<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603952</url>
  </required_header>
  <id_info>
    <org_study_id>D6000C00002</org_study_id>
    <nct_id>NCT02603952</nct_id>
  </id_info>
  <brief_title>A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza</brief_title>
  <acronym>MEDI8852</acronym>
  <official_title>A Phase 2a, Randomized, Partial Double-blind, Single Dose, Active-controlled, Dose Ranging Study to Evaluate the Safety of MEDI8852 in Adults With Acute, Uncomplicated Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and tolerability of a single dose of MEDI8852
      when given with oseltamivir, the safety and tolerability of oseltamivir alone, and the safety
      and tolerability of a single dose of MEDI8852 alone in adult subjects with acute,
      uncomplicated influenza caused by Type A strains.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MEDI8852 phase 2a study will evaluate the safety and tolerability of a single intravenous
      (IV) dose of MEDI8852 administered in conjunction with oseltamivir, the safety and
      tolerability of oseltamivir alone and the safety and tolerability of a single IV dose of
      MEDI8852 alone in adult subjects with confirmed acute, uncomplicated influenza caused by Type
      A strains. Enrollment is planned at approximately 50 sites in the United States, South
      Africa, and Australia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurence of Adverse Events</measure>
    <time_frame>Through Day 28</time_frame>
    <description>Occurence of adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurence of Serious Adverse Events</measure>
    <time_frame>Through Study Day 101</time_frame>
    <description>Occurence of serious adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited Influenza Symptoms</measure>
    <time_frame>Through Day 10</time_frame>
    <description>Occurence of solicited influenza sypmtoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurence of Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>Through Day 101</time_frame>
    <description>Occurence of Adverse Events of Special Interest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of influenza viral shedding by qRT-PCR.</measure>
    <time_frame>Through Study Day 7</time_frame>
    <description>Evaluation of occurence of influenza viral shedding at baseline (Day 1), Day 3, 5, and 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the proportion of subjects with resistance to oseltamivir.</measure>
    <time_frame>Baseline through Day 7</time_frame>
    <description>Evaluate Oseltamivir resistance-associated mutations at baseline (Day 1) and following treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate viral resistance to MEDI8852 through genotypic analysis.</measure>
    <time_frame>Baseline through Day 7</time_frame>
    <description>Evaluate genotypic analysis of virus to MEDI8852 at baseline (Day 1) and following treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">375</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Oseltamivir + low dose MEDI8852MEDI8852</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Doses of MEDI8852 + Oseltamivir will be studied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir + high dose MEDI8852</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose of MEDI8852 + Oseltamivir will be studied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oseltamivir in comparison to placebo will be studied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI8852</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI8852 will be studied given intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>Commercially supplied capsule.</description>
    <arm_group_label>Oseltamivir + low dose MEDI8852MEDI8852</arm_group_label>
    <arm_group_label>Oseltamivir + high dose MEDI8852</arm_group_label>
    <arm_group_label>Oseltamivir + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI8852</intervention_name>
    <description>MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion.</description>
    <arm_group_label>Oseltamivir + low dose MEDI8852MEDI8852</arm_group_label>
    <arm_group_label>Oseltamivir + high dose MEDI8852</arm_group_label>
    <arm_group_label>MEDI8852</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Salt-water solution containing no active ingredients.</description>
    <arm_group_label>Oseltamivir + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 through 65 years at the time of screening.

          -  Symptomatic presumptive Influenza A infection with onset of symptoms ≤ 5 days prior to
             MEDI8852 administration and defined as the presence of:

          -  Fever of ≥ 38.0ºC (100.4°F) at screening AND

          -  ≥ 1 moderate systemic symptom (headache, malaise, myalgia, sweats and/or chills, or
             fatigue) AND

               -  1 moderate respiratory symptom (cough, sore throat, or nasal symptoms)

          -  Influenza A infection confirmed with positive rapid antigen test

          -  Able to complete the follow-up period through Day 101 as required by protocol
             (including telephone follow-up for Days 11 to 101)

          -  Females of childbearing potential who are sexually active with a nonsterilized male
             partner must use a highly effective method of contraception for at least 2 days prior
             to the first dose of investigational product and must agree to continue using such
             precautions through Day 101 of the study

        Exclusion Criteria:

          -  Hospitalized subjects.

          -  Receipt of influenza antiviral therapy within the preceding 14 days.

          -  Receipt of immunoglobulin or blood products within 6 months prior to screening.

          -  Known immunodeficiency due to illness, including HIV, or due to drugs, including any
             course of glucocorticoid therapy exceeding 2 weeks of prednisone or equivalent at a
             dose of 20 mg daily or every other day within 6 months prior to screening.

          -  Current clinical evidence of pneumonia.

          -  Active bacterial infection requiring treatment with oral or parenteral antibiotics.

          -  History of malignancy other than treated non-melanoma skin cancers or locally-treated
             cervical cancer in previous 3 years.

          -  Any planned surgical procedure before completion of Day 101.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smithfield</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brandfort</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thabazimbi</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Welkom</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Influenza A</keyword>
  <keyword>Flu</keyword>
  <keyword>Flu A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 15, 2018</submitted>
    <returned>March 15, 2018</returned>
    <submitted>May 7, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

